The GVHD Therapeutics Market is Forecast to Show Moderate Growth until 2018

Tuesday 21 February 2012, Amsterdam

The report is an essential source of information and analysis on the global Graft Versus Host Disease (GVHD) Therapeutics market. The report identifies the key trends shaping and driving the global Graft Versus Host Disease (GVHD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Graft Versus Host Disease (GVHD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The GVHD Therapeutics Market is Forecast to Show Moderate Growth until 2018

The estimates that the global Graft Versus Host Disease (GVHD) therapeutics market was worth $261.6m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 11.3% to reach $615.1m by 2018. This moderate growth is primarily attributed to the strong pipeline landscape, increase in the number of Hematopoietic Stem Cell Transplants (HSCTs) and the launch of new first-in-class drugs with improved safety and efficacy profiles.

See figure: GVHD Therapeutics, Global, Revenue and Market Forecast ($m), 2005-2018

Unmet Need Continues to Challenge the Pipeline Drugs

The analysis shows that the current market landscape is weak as generic immunosuppressive agents are used off-label. These products have moderate levels of efficacy and safety and as a result, GVHD remains a major cause of mortality following HSCT. The current market has significant unmet need and thus provides significant potential for pipeline drugs that are stronger in terms of efficacy and safety. However, considering the fact that a majority of the pipeline products are first-in-class but are Mesenchymal Stem Cell (MSC) therapies aimed primarily at the prevention of GVHD, the therapeutic market will continue to remain dominated by the existing drugs. If approved, these new therapies will create a new market.

Increased Use of HSCTs for Hematologic Malignancies

HSCT is a treatment option for certain types of leukemia and lymphoma such as Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and Myelodysplastic Syndrome (MDS) when chemotherapy and/or radiation therapy fail. The past two decades have seen a gradual increase in the number of allogeneic HSCTs performed annually. The increasing incidence of leukemia has led to more elderly patients receiving reduced-intensity or non-myeloablative transplants because the risk of ALL, ALL and MDS increases in people above the age of 50 years. GVHD risk also increases with age, meaning that incidence is increasing and the market is growing.